Ramucirumab Plus FOLFIRI Improves Overall Survival in Patients with Metastatic Colorectal Cancer
the Cancer Therapy Advisor take:
Eli Lilly and Company has announced that ramucirumab (Cyramza) plus leucovorin, fluorouracil (5-FU), and irinotecan (FOLFIRI), compared with placebo, improved overall survival in patients with metastatic colorectal cancer (mCRC) whose disease progressed after bevacizumab, oxaliplatin, and a fluoropyrimidine.
In addition, the global, randomized, double-blind, phase 3 study demonstrated a statistically significant improvement in progression-free survival (PFS) in patients that took ramucirumab in combination with FOLFIRI compared to those that took placebo plus FOLFIRI. The most common adverse effects in patients taking the ramucirumab combination were diarrhea, fatigue, hypertension, and neutropenia.
The U.S. Food and Drug Administration (FDA) initially approved ramucirumab for intravenous infusion in 2014 for the treatment of patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma whose disease progressed after fluoropyrimidine- or platinum-containing chemotherapy. The most common adverse effects associated with ramucirumab are hypertension and diarrhea. Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist. Patients receiving ramucirumab should be premedicated with an intravenous histamine antagonist like diphenhydramine hydrochloride.
Eli Lilly and Company plans to submit ramucirumab to the U.S. FDA for the treatment of patients with mCRC whose disease has progressed after bevacizumab, oxaliplatin, and a fluoropyrimidine.
Ramucirumab plus fluorouracil improved overall survival in patients with metastatic colorectal cancer.
Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA™) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.
The global, randomized, double-blind study compared ramucirumab plus FOLFIRI to placebo plus FOLFIRI as a second-line treatment in patients with mCRC after treatment with bevacizumab, oxaliplatin and a fluoropyrimidine in the first-line setting. RAISE showed a statistically significant improvement in overall survival in patients treated with ramucirumab plus FOLFIRI compared to placebo plus FOLFIRI.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Immunotherapy in Glioblastoma: Peaks and Pits
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed